Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#1471 Chemotherapy for Stage IV Sporadic Pancreatic Neuroendocrine Tumors (pNET): Are Partial Responses to Post-first Line Chemotherapy Predictable by Response/Type of First Line Chemotherapy?

Introduction: Three types of chemotherapy are recommended for stage IV pancreatic neuroendocrine tumors (pNETs): streptozocin (STZ)-, dacarbazine (DCZ)- and oxaliplatin (OX)-based. Whether cross resistance exists is unknown.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Marotta V

Authors: Marotta V, Malka D, Walter T, Do Cao C, Faggiano A,

Keywords: pancreatic neuroendocrine tumor, chemotherapy,

#1452 Prognosis of Stage IV Sporadic Pancreatic Neuroendocrine Tumors (pNET): Tumor Slope is Prognostic Together with Tumor Burden and Grade

Introduction: Currently, no prognostic stratification exists in stage IV pNET patients.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Marotta V

Authors: Marotta V, Malka D, Walter T, Do Cao C, Borget I,

Keywords: stage IV, pancreatic neuroendocrine tumor, prognosis, survival,

#1191 Efficacy of Lanreotide versus Follow-up in Early-stage Duodeno-Pancreatic Neuroendocrine Tumors (NETs) Related to Multiple Endocrine Neoplasia Type 1 (MEN1): Preliminary Data

Introduction: Surgery is the only curative approach for NETs, representing the first-line therapy. As most pts with MEN1 have multiple duodeno-pancreatic NETs, cure is generally not possible, unless to adopt radical surgery. Somatostatin analogues (SSAs) represent one of the main therapeutic option in functioning well-differentiated NETs. There are no perspective studies focusing on MEN1-related NETs.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Ramundo V

Authors: Ramundo V, Marciello F, Modica R, Marotta V, Pizza G,

Keywords: Multiple Endocrine Neoplasia type 1, Lanreotide, Duodeno-pancreatic NETs.,

#1187 High-Dose Treatment with Somatostatin Analogs in Neuroendocrine Tumors

Introduction: Somatostatin analogs (SSA) effectively control symptoms in neuroendocrine tumours (NET), besides showing antiproliferative activity. In progressive or metastatic NET, increasing SSA dose or shortening the dosing interval are common clinical practice, though empirical.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Modica R

Authors: Modica R, Ramundo V, Marciello F, Marotta V, Pizza G,

Keywords: Somatostatin Analogs, Neuroendocrine Tumors,

#904 Role of Metformin on Recurrence-Free Survival (RFS) in Neuroendocrine Tumors (NET)

Introduction: Recent data suggest metformin (Met) has antineoplastic properties in different type of cancer. Effects of Met have never been investigated in NET.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Marciello F

Authors: Marciello F, Del Prete M, Marotta V, Ramundo V, Buonomano P,

Keywords: prognosis, metformin, RFS, survival,